Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies

Human Molecular Genetics

Volumn 24, Issue 17, 2015, Pages 4916-4932

  Rouillon, Jérémy ^a   Poupiot, Jérôme ^a   Zocevic, Aleksandar ^a   Amor, Fatima ^a   Léger, Thibaut ^b   Garcia, Camille ^b   Camadro, Jean Michel ^b   Wong, Brenda ^c   Pinilla, Robin ^a   Cosette, Jérémie ^a   Coenen Stass, Anna M L ^d   Mcclorey, Graham ^d   Roberts, Thomas C ^d,e   Wood, Matthew J A ^d   Servais, Laurent ^f   Udd, Bjarne ^g   Voit, Thomas ^h,i   Richard, Isabelle ^a   Svinartchouk, Fedor ^a  

^a GÉNÉTHON   (France)

^b INSTITUT JACQUES MONOD   (France)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UMRS974 Institut de Myologie   (France)

^g UNIVERSITY OF HELSINKI   (Finland)

^h CNRS   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SARCOGLYCAN; ARGININE RICH CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; MYOFIBRILLAR STRUCTURAL PROTEIN MYOMESIN 3; MYOMESIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CONNECTIN; CREATINE KINASE; MYOM3 PROTEIN, HUMAN; PLASMA PROTEIN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; ANIMAL; BLOOD; CASE CONTROL STUDY; DISEASE MODEL; METABOLISM; MUSCULAR DYSTROPHIES; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOMARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CONNECTIN; CREATINE KINASE; DISEASE MODELS, ANIMAL; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; PROTEOMICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941930125     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv214     Document Type: Article

References (74)

1. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G. and Campbell, K.P. (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 345, 315-319.
2. Cullen, M.J. and Mastaglia, F.L. (1980) Morphological changes in dystrophic muscle. Br. Med. Bull., 36, 145-152.
3. Poysky, J. (2007) Behavior patterns in Duchenne muscular dystrophy: report on the Parent Project Muscular Dystrophy behavior workshop 8-9 of December 2006, Philadelphia, USA. Neuromuscul. Disord., 17, 986-994.
4. Melacini, P., Fanin, M., Duggan, D.J., Freda, M.P., Berardinelli, A., Danieli, G.A., Barchitta, A., Hoffman, E.P., Dalla Volta, S. and Angelini, C. (1999) Heart involvement inmuscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve, 22, 473-479.
5. Barresi, R., Di Blasi, C., Negri, T., Brugnoni, R., Vitali, A., Felisari, G., Salandi, A., Daniel, S., Cornelio, F., Morandi, L. and Mora, M. (2000) Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J. Med. Genet., 37, 102-107.
6. Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E. et al. (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther., 20, 443-455.
7. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M.E., Bourke, J., Wells, D.J. et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 595-605.
8. Goemans, N.M., Tulinius, M., van den Akker, J.T., Burm, B.E., Ekhart, P.F., Heuvelmans, N., Holling, T., Janson, A.A., Platenburg, G.J., Sipkens, J.A. et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 364, 1513-1522.
9. Flanigan, K.M., Voit, T., Rosales, X.Q., Servais, L., Kraus, J.E., Wardell, C., Morgan, A., Dorricott, S., Nakielny, J., Quarcoo, N. et al. (2014) Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul. Disord., 24, 16-24.
10. Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S.J., Eagle, M., Guglieri, M., Hood, S. et al. (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol., 13, 987-996.
11. Finkel, R.S., Flanigan, K.M., Wong, B., Bonnemann, C., Sampson, J., Sweeney, H.L., Reha, A., Northcutt, V.J., Elfring, G., Barth, J. et al. (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PloS one, 8, e81302.
12. Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G.P., Connolly, A.M., Day, J.W., Flanigan, K.M., Goemans, N. et al. (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve, 50, 477-487.
13. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., Coley, B.D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B.J., Conlon, T. et al. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol., 68, 629-638.
14. Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N.B., Leturcq, F., Laforet, P., Maisonobe, T., Amouri, R., Haddad, H. et al. (2012) A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain, 135, 483-492.
15. Berard, C., Payan, C., Hodgkinson, I. and Fermanian, J. (2005) A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul. Disord., 15, 463-470.
16. Lue, Y.J., Lin, R.F., Chen, S.S. and Lu, Y.M. (2009) Measurement of the functional status of patients with different types of muscular dystrophy. Kaohsiung J. Med. Sci., 25, 325-333.
17. Servais, L., Deconinck, N., Moraux, A., Benali, M., Canal, A., Van Parys, F., Vereecke, W., Wittevrongel, S., Mayer, M., Desguerre, I. et al. (2013) Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul. Disord., 23, 139-148.
18. Wokke, B.H., Bos, C., Reijnierse, M., van Rijswijk, C.S., Eggers, H., Webb, A., Verschuuren, J.J. and Kan, H.E. (2013) Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. J. Magn. Reson. Imaging, 38, 619-624.
19. Cacchiarelli, D., Legnini, I., Martone, J., Cazzella, V., D'Amico, A., Bertini, E. and Bozzoni, I. (2011) miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol. Med., 3, 258-265.
20. Vignier, N., Amor, F., Fogel, P., Duvallet, A., Poupiot, J., Charrier, S., Arock, M., Montus, M., Nelson, I., Richard, I. et al. (2013) Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PloS one, 8, e55281.
21. Roberts, T.C., Godfrey, C., McClorey, G., Vader, P., Briggs, D., Gardiner, C., Aoki, Y., Sargent, I., Morgan, J.E. and Wood, M. J. (2013) Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Res., 41, 9500-9513.
22. Rouillon, J., Zocevic, A., Leger, T., Garcia, C., Camadro, J.M., Udd, B., Wong, B., Servais, L., Voit, T. and Svinartchouk, F. (2014) Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscul. Disord., 24, 563-573.
23. Zatz, M., Rapaport, D., Vainzof, M., Passos-Bueno, M.R., Bortolini, E.R., Pavanello Rde, C. and Peres, C.A. (1991) Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. J. Neurol. Sci., 102, 190-196.
24. Gasper, M.C. and Gilchrist, J.M. (2005) Creatine kinase: a review of its use in the diagnosis of muscle disease. Med. Health R. I., 88, 398, 400-394.
25. Mendell, J.R., Shilling, C., Leslie, N.D., Flanigan, K.M., al-Dahhak, R., Gastier-Foster, J., Kneile, K., Dunn, D.M., Duval, B., Aoyagi, A. et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol., 71, 304-313.
26. Meng, Z. and Veenstra, T.D. (2007) Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers. Proteomics Clin. Appl., 1, 747-757.
27. Moat, S.J., Bradley, D.M., Salmon, R., Clarke, A. and Hartley, L. (2013) Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur. J. Hum. Genet., 21, 1049-1053.
28. Hathout, Y., Marathi, R.L., Rayavarapu, S., Zhang, A., Brown, K. J., Seol, H., Gordish-Dressman, H., Cirak, S., Bello, L., Nagaraju, K. et al. (2014) Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum. Mol. Genet., 23, 6458-6469.
29. Schoenauer, R., Lange, S., Hirschy, A., Ehler, E., Perriard, J.C. and Agarkova, I. (2008) Myomesin 3, a novel structural component of the M-band in striated muscle. J. Mol. Biol., 376, 338-351.
30. Kornegay, J.N., Bogan, J.R., Bogan, D.J., Childers, M.K., Li, J., Nghiem, P., Detwiler, D.A., Larsen, C.A., Grange, R.W., Bhavaraju-Sanka, R.K. et al. (2012) Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome, 23, 85-108.
31. Richard, I., Roudaut, C., Marchand, S., Baghdiguian, S., Herasse, M., Stockholm, D., Ono, Y., Suel, L., Bourg, N., Sorimachi, H. et al. (2000) Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/ nuclear factor kappaB pathway perturbation in mice. J. Cell Biol., 151, 1583-1590.
32. Lostal, W., Bartoli, M., Bourg, N., Roudaut, C., Bentaib, A., Miyake, K., Guerchet, N., Fougerousse, F., McNeil, P. and Richard, I. (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet., 19, 1897-1907.
33. Hack, A.A., Ly, C.T., Jiang, F., Clendenin, C.J., Sigrist, K.S.,Wollmann, R.L. and McNally, E.M. (1998) Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J. Cell Biol., 142, 1279-1287.
34. Duclos, F., Straub, V., Moore, S.A., Venzke, D.P., Hrstka, R.F., Crosbie, R.H., Durbeej, M., Lebakken, C.S., Ettinger, A.J., van der Meulen, J. et al. (1998) Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J. Cell Biol., 142, 1461-1471.
35. Cullen, M.J. and Jaros, E. (1988) Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy. Acta Neuropathol., 77, 69-81.
36. McArdle, A., Edwards, R.H. and Jackson, M.J. (1994) Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse. Muscle Nerve, 17, 1378-1384.
37. Wooddell, C.I., Zhang, G., Griffin, J.B., Hegge, J.O., Huss, T. and Wolff, J.A. (2010) Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice. Muscle Nerve, 41, 487-499.
38. Brussee, V., Tardif, F. and Tremblay, J.P. (1997) Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromuscul. Disord., 7, 487-492.
39. Vilquin, J.T., Brussee, V., Asselin, I., Kinoshita, I., Gingras, M. and Tremblay, J.P. (1998) Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve, 21, 567-576.
40. Webster, C., Silberstein, L., Hays, A.P. and Blau, H.M. (1988) Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell, 52, 503-513.
41. Yin, H., Saleh, A.F., Betts, C., Camelliti, P., Seow, Y., Ashraf, S., Arzumanov, A.,Hammond, S., Merritt, T., Gait, M.J. et al. (2011) Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther., 19, 1295-1303.
42. Betts, C., Saleh, A.F., Arzumanov, A.A., Hammond, S.M., Godfrey, C., Coursindel, T., Gait, M.J. and Wood, M.J. (2012) Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol. Ther. Nucleic Acids, 1, e38.
43. Jearawiriyapaisarn, N., Moulton, H.M., Sazani, P., Kole, R. and Willis, M.S. (2010) Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc. Res., 85, 444-453.
44. Duguez, S., Duddy, W., Johnston, H., Laine, J., Le Bihan, M.C., Brown, K.J., Bigot, A., Hathout, Y., Butler-Browne, G. and Partridge, T. (2013) Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. Cell. Mol. Life Sci., 70, 2159-2174.
45. Mussini, E., Cornelio, F., Colombo, L., De Ponte, G., Giudici, G., Cotellessa, L. and Marcucci, F. (1984) Increased myofibrillar protein catabolism in duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine. Muscle Nerve, 7, 388-391.
46. McKeran, R.O., Halliday, D. and Purkiss, P. (1977) Increased myofibrillar protein catabolism in Duchenne muscular dystrophy measured by 3-methylhistidine excretion in the urine. J. Neurol. Neurosurg. Psychiatry, 40, 979-981.
47. Carlson, C.G., Rutter, J., Bledsoe, C., Singh, R., Hoff, H., Bruemmer, K., Sesti, J., Gatti, F., Berge, J. and McCarthy, L. (2010) A simple protocol for assessing inter-trial and inter-examiner reliability for two noninvasive measures of limb muscle strength. J. Neurosci. Methods, 186, 226-230.
48. Kobayashi, Y.M., Rader, E.P., Crawford, R.W. and Campbell, K. P. (2012) Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies. Neuromuscul. Disord., 22, 34-42.
49. Hathout,Y.,Marathi, R.L.,Rayavarapu, S.,Zhang, A., Brown,K.J., Seol, H., Gordish-Dressman, H., Cirak, S., Bello, L., Nagaraju, K. et al. (2014) Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum. Mol. Genet., 23, 6458-6469.
50. Mendell, J.R. and Lloyd-Puryear, M. (2013) Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve, 48, 21-26.
51. Turner, D.C., Wallimann, T. and Eppenberger, H.M. (1973) A protein that binds specifically to the M-line of skeletal muscle is identified as the muscle form of creatine kinase. Proc. Natl. Acad. Sci. U. S. A., 70, 702-705.
52. Wallimann, T., Moser, H. and Eppenberger, H.M. (1983) Isoenzyme-specific localization of M-line bound creatine kinase in myogenic cells. J. Muscle Res. Cell Motil., 4, 429-441.
53. Stolz, M. and Wallimann, T. (1998) Myofibrillar interaction of cytosolic creatine kinase (CK) isoenzymes: allocation of N-terminal binding epitope in MM-CK and BB-CK. J. Cell Sci., 111(Pt 9), 1207-1216.
54. He, B., Tang, R.H.,Weisleder, N., Xiao, B., Yuan, Z., Cai, C., Zhu, H., Lin, P., Qiao, C., Li, J. et al. (2012) Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-Sarcoglycan-deficient hamsters. Mol. Ther., 20, 727-735.
55. Masters, C.J., Reid, S. and Don, M. (1987) Glycolysis-new concepts in an old pathway. Mol. Cell. Biochem., 76, 3-14.
56. Gizak, A., Rakus, D. and Dzugaj, A. (2003) Immunohistochemical localization of human fructose-1,6-bisphosphatase in subcellular structures of myocytes. Histol. Histopathol., 18, 135-142.
57. Wang, Y., Kinzie, E., Berger, F.G., Lim, S.K. and Baumann, H. (2001) Haptoglobin, an inflammation-inducible plasma protein. Redox Rep., 6, 379-385.
58. Le Borgne, F., Guyot, S., Logerot, M., Beney, L., Gervais, P. and Demarquoy, J. (2012) Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine. PloS one, 7, e49346.
59. Stapleton, D.I., Lau, X., Flores, M., Trieu, J., Gehrig, S.M., Chee, A., Naim, T., Lynch, G.S. and Koopman, R. (2014) Dysfunctional muscle and liver glycogen metabolism in mdx dystrophic mice. PloS one, 9, e91514.
60. Agarkova, I. and Perriard, J.C. (2005) The M-band: an elastic web that crosslinks thick filaments in the center of the sarcomere. Trends Cell Biol., 15, 477-485.
61. Lange, S., Himmel, M., Auerbach, D., Agarkova, I., Hayess, K., Furst, D.O., Perriard, J.C. and Ehler, E. (2005) Dimerisation of myomesin: implications for the structure of the sarcomeric M-band. J. Mol. Biol., 345, 289-298.
62. Schoenauer, R., Bertoncini, P., Machaidze, G., Aebi, U., Perriard, J.C., Hegner, M. and Agarkova, I. (2005) Myomesin is a molecular spring with adaptable elasticity. J. Mol. Biol., 349, 367-379.
63. Alderton, J.M. and Steinhardt, R.A. (2000) How calcium influx through calciumleak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc. Med., 10, 268-272.
64. Cai, C., Masumiya, H., Weisleder, N., Matsuda, N., Nishi, M., Hwang, M., Ko, J.K., Lin, P., Thornton, A., Zhao, X. et al. (2009) MG53 nucleates assembly of cell membrane repair machinery. Nat. Cell Biol., 11, 56-64.
65. Carpenter, S. and Karpati, G. (1979) Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired. Brain, 102, 147-161.
66. Lange, S., Xiang, F., Yakovenko, A., Vihola, A., Hackman, P., Rostkova, E., Kristensen, J., Brandmeier, B., Franzen, G., Hedberg, B. et al. (2005) The kinase domain of titin controls muscle gene expression and protein turnover. Science, 308, 1599-1603.
67. Roberts, T.C., Blomberg, K.E., McClorey, G., El Andaloussi, S., Godfrey, C., Betts, C., Coursindel, T., Gait, M.J., Smith, C.I. andWood, M.J. (2012) Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids, 1, e39.
68. Ayoglu, B., Chaouch, A., Lochmuller, H., Politano, L., Bertini, E., Spitali, P., Hiller, M., Niks, E.H., Gualandi, F., Ponten, F. et al. (2014) Affinity proteomics within rare diseases: a BIONMD study for blood biomarkers of muscular dystrophies. EMBO Mol. Med., 6, 918-936.
69. Chapman, V.M., Miller, D.R., Armstrong, D. and Caskey, C.T. (1989) Recovery of induced mutations for X chromosomelinked muscular dystrophy in mice. Proc. Natl. Acad. Sci. U. S. A., 86, 1292-1296.
70. Laure, L., Suel, L., Roudaut, C., Bourg, N., Ouali, A., Bartoli, M., Richard, I. and Daniele, N. (2009) Cardiac ankyrin repeat protein is a marker of skeletal muscle pathological remodelling. FEBS J., 276, 669-684.
71. Boisgerault, F., Gross, D.A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I. and Galy, A. (2013) Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer. Hum. Gene Ther., 24, 393-405.
72. Smith, R.H., Levy, J.R. and Kotin, R.M. (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther., 17, 1888-1896.
73. Carlson, C.G. and Makiejus, R.V. (1990) A noninvasive procedure to detect muscle weakness in the mdx mouse. Muscle Nerve, 13, 480-484.
74. Fougerousse, F., Bartoli, M., Poupiot, J., Arandel, L., Durand, M., Guerchet, N., Gicquel, E., Danos, O. and Richard, I. (2007) Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector. Mol. Ther., 15, 53-61.